Event Panel Schedule

Clin­i­cal In­sights of New Rapid­ly Act­ing, NM­DA-based An­tide­pres­sants
Robert Besthof , CMO / NeuroRx
Developing first Glx targeted antidepressant to address suicidality in bipolar depression. Lead candidate, NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w…

NK cell ex­pan­sion and pro­lif­er­a­tion with PM21 par­ti­cles: ad­junc­tive ther­a­py for he­ma­topoi­et­ic stem cell tran­s­plan­ta­tion and po­ten­tial treat­ment for both liquid and solid tu­mors
Kiadis Pharma N.V.
Arthur Lahr , CEO / Kiadis Pharma N.V.
Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he…

Three clin­i­cal-stage cell ther­a­py pro­grams in dry age-re­lat­ed mac­u­lar de­gen­er­a­tion, spi­nal cord in­jury, and on­col­o­gy
Lineage Cell Therapeutics
Brian Culley , CEO / Lineage Cell Therapeutics
Mr. Culley joined BioTime as CEO in September 2018. Prior to joining BioTime, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management…

SCLC: Re­cent ap­pro­vals in first and third line could be joined with Lur­binecte­din in 2nd line
PharmaMar SA
Pascal Besman , Chief Operating Officer (PharmaMar U.S.) / PharmaMar SA
Prior to joining JMP, Pascal was a partner and institutional salesperson at Maxim and also ThinkEquity for three years. He previously served as a senior vice president at UBS and has held equity sales positions at Bear Stearns, Lehman Brothers and…

On­co­lyt­ic ade­n­ovirus armed w im­mune sti­m­u­lat­ing trans­gene tar­get­ing bas­ket of I-O in­di­ca­tions
Torbjørn Furuseth , Chief Financial Officer / Targovax
An experienced executive with a broad background within life science. He joins from the clinical stage immune-oncology company Lytix Biopharma, where he has served as CFO and conducted several financing rounds. Prior to this, he was EVP Innovation at…

E-CEL® (En­gi­neered En­dothe­lial Cell) Ther­a­py and Vas­cu­lar Niche Bi­ol­o­gy
Angiocrine Bioscience
Paul Finnegan , CEO / Angiocrine Bioscience
Dr. Finnegan is Chief Executive Officer of Angiocrine Bioscience. He has more than 20 years of life science management experience in the biotechnology, pharmaceutical, and healthcare industries
Export to Excel